Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.

ABSTRACT:

Background

Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19. However, no studies have evaluated adverse events and effectiveness of mAbs in pregnant persons compared with no mAb treatment.

Objective

To determine the frequency of drug-related adverse events and obstetric-associated safety outcomes after treatment with mAb compared with no mAb treatment of pregnant persons, and the association between mAb treatment and a composite of 28-day COVID-19-related hospital admission or emergency department (ED) visit, COVID-19-associated delivery, or mortality.

Design

Retrospective, propensity score-matched, cohort study.

Setting

UPMC Health System from 30 April 2021 to 21 January 2022.

Pa

SUBMITTER: McCreary EK 

PROVIDER: S-EPMC9747093 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature